ZIOPHARM Oncology Inc (ZIOP) News
Filter ZIOP News Items
ZIOP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ZIOP News Highlights
- ZIOP's 30 day story count now stands at 4.
- Over the past 7 days, the trend for ZIOP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ZIOP are FORD.
Latest ZIOP News From Around the Web
Below are the latest news stories about Ziopharm Oncology Inc that investors may wish to consider to help them evaluate ZIOP as an investment opportunity.
Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos TherapeuticsPhase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose the first patient in 1H 2022 Phase 1/2 IND amended to include four additional TCRs, bringing the total number of evaluable TCRs to 10, further expanding number of eligible patientsIn-house cGMP manufacturing facility is operational to support internal clinical development programsCompany changes name to Alaunos Therapeutics reflecting renewed |
Allred Capital Management, LLC Buys Tractor Supply Co, Equifax Inc, NextEra Energy Inc, Sells ...Investment company Allred Capital Management, LLC (Current Portfolio) buys Tractor Supply Co, Equifax Inc, NextEra Energy Inc, Newmont Corp, Paychex Inc, sells iShares S&P 500 Growth ETF, Vanguard Total Bond Market ETF, Ford Motor Co, Adobe Inc, AT&T Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Allred Capital Management, LLC. |
Is ZIOPHARM Oncology (NASDAQ:ZIOP) Weighed On By Its Debt Load?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the... |
Why Ziopharm Oncology Shares Rose 10.5% on WednesdayThe clinical-stage biopharmaceutical company is examining non-viral T-cell receptor therapies (TCR-T) to fight cancer. There are two reasons for Ziopharm's climb. First, it's a reaction to hitting its 52-week low as investors saw a potential bargain. |
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Expected to Post Earnings of -$0.09 Per ShareEquities analysts expect ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to report earnings of ($0.09) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for ZIOPHARM Oncologys earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.11). ZIOPHARM Oncology reported earnings of ($0.11) per share during the same [] |
Gateway Advisory LLC Buys Shares of 15,301 ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)Gateway Advisory LLC bought a new stake in ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 15,301 shares of the biotechnology companys stock, valued at approximately $28,000. Other large investors also recently added [] |
Zacks: Brokerages Expect ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to Announce -$0.09 EPSBrokerages expect ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to announce earnings of ($0.09) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for ZIOPHARM Oncology’s earnings, with the lowest EPS estimate coming in at ($0.11) and the highest estimate coming in at ($0.07). ZIOPHARM Oncology reported earnings of ($0.11) per share in […] |
ECMOHO Limited Announces the Appointment of independent director of the BoardSHANGHAI, China, Dec. 06, 2021 (GLOBE NEWSWIRE) -- ECMOHO Limited (Nasdaq: MOHO) (“ECMOHO” or the “Company”), an integrated solutions provider in the health and wellness market in China, today announced a change in its board of directors (the “Board”). Mr. Greg Ye tendered to the Board his resignation as an independent director of the Board, the chair and a member of the audit committee of the Board and a member of the Nominating and Corporate Governance Committee of the Board for personal reaso |
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Stake Boosted by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD increased its holdings in ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) by 8.8% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 102,936 shares of the biotechnology companys stock after purchasing an additional 8,331 shares during the quarter. Price T Rowe Associates Inc. MDs holdings in ZIOPHARM Oncology were worth $272,000 [] |
ZIOPHARM Oncology (NASDAQ:ZIOP) Rating Reiterated by HC WainwrightZIOPHARM Oncology (NASDAQ:ZIOP)s stock had its hold rating reissued by analysts at HC Wainwright in a report issued on Monday, Price Targets.com reports. Several other equities research analysts have also weighed in on the company. Lake Street Capital cut their target price on ZIOPHARM Oncology from $7.00 to $3.50 and set a buy rating on [] |